North America is Dominant in the Global Leukemia Therapeutics Market

The global leukemia therapeutics market is expected to witness a CAGR of 6.2% during the forecast period to reach revenue of more than $17 billion by 2025. Read below to discover how the market will perform.
Spread the Word
Listed Under

* Luekemia

* Health

* Tampa - Florida - US

* Reports

TAMPA, Fla. - Jan. 23, 2020 - PRLog -- With its recently published study Global Leukemia Therapeutics Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025, Infoholic Research forecasts that the global leukemia therapeutics market will continue to grow, owing to increasing incidence of leukemia cases across the globe, rising elderly population, and advent of innovative therapies. A promising pipeline of the drug, increased approval of new drugs, and substantial opportunities in emerging economies are anticipated to support the market growth during the forecast period 2019–2025.

The global leukemia therapeutics market, by disease type, is segmented into chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), and acute myeloid leukemia (AML). Among these, the chronic myeloid leukemia segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR by 2025. The increased prevalence rate of CML and the obtainability of huge number of treatment options make the segment the largest shareholder in the global leukemia therapeutics market. The market, in terms of molecule type analysis, is segmented into small molecules and biologics. The small molecules segment occupied a maximum share and biologics is expected to grow at a high CAGR during the forecast period 2019–2025.

In December 2019, Merck signed a definitive agreement to purchase cancer drug developer "ArQule" through an acquisition subsidiary, for $2.7 billion. If the deal is successful, Merck will get a promising early-stage compound that has the potential to challenge a blockbuster leukemia drug manufactured by the rival company "AbbVie". ArQule's leading investigational candidate ARQ 531 is a small molecule oral BTK inhibitor currently in Phase 2 dose-expansion study for the treatment of leukemia. Merck expects to finalize the transaction in the first quarter of 2020.

Access full report summary @

Many companies are gaining approvals for their drugs, which is aiding to have significant hold in the market. The global leukemia therapeutics market is segmented in the regions of North America, Europe, Asia Pacific, and Rest of the World. North America held a significant market share in 2018.  The presence of established healthcare infrastructure, a high patient base for the disease, increasing awareness on personalized medicine, and the existence of reputed players in the region make North America a dominant shareholder in the global leukemia therapeutics market.
Request for sample report @

No.45/1, 5th Floor, Leo Shopping Complex,
Residency Road Cross, Bengaluru – 560025, India
Location:Tampa - Florida - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share